Silence Therapeutics PLC Silence Therapeutics advances next RNAi medicine (9040K)
19 December 2018 - 6:00PM
UK Regulatory
TIDMSLN
RNS Number : 9040K
Silence Therapeutics PLC
19 December 2018
Silence Therapeutics advances next RNAi medicine
Lipoprotein(a) targeting, an exciting approach to address
cardiovascular disease
December 19, 2018
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the
Company") a leader in the discovery, development and delivery of
novel RNA therapeutics for the treatment of serious diseases,
announces the addition of a new siRNA (short interfering RNA) asset
to its pre-clinical pipeline for the potential treatment of
cardiovascular disease.
The product candidate, SLN360, silences apolipoprotein (a), a
component of lipoprotein(a) ("LP(a)"), which is a highly validated
target based on extensive human genetic data. Elevated LP(a) levels
have been associated with increased risk of cardiovascular disease,
independent of additional risk factors.
Data generated in non-human primates show that Silence's
proprietary GalNAc-siRNA candidate SLN360 yields potent and durable
serum LP(a) knockdown for over six weeks following a low single
dose, with higher doses resulting in sustained knockdown (>90%)
for at least two months with no trend back to baseline levels
observed. These performance data, together with the subcutaneous
administration route and safety profile of our molecules, support
an infrequent and patient-friendly dosing regimen. The IND/CTA for
SLN360 is anticipated to be filed in the second half of 2020.
David Horn Solomon, Chief Executive Officer of Silence
Therapeutics, commented:
"We are excited to add SLN360, our new LP(a) targeting siRNA
medicine, to our pipeline of wholly owned assets aimed at
addressing areas of significant unmet need. High LP(a) levels in
humans increase the probability of significant cardiovascular
disease and lowering these levels is associated with reducing
cardiovascular risks and disease. Our data suggest that SLN360
significantly reduces serum LP(a) in non-human primates for up to
two months and ultimately will use patient convenient sub-cutaneous
dosing. We are poised to advance SLN360 towards the clinic as a new
medicine for patients with significant cardiovascular risk. "
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Dr David Horn Solomon, Chief Executive 6900
Officer
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0)20 7418
James Steel/Oliver Jackson 8900
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott / Angela Gray
silencetherapeutics@consilium-comms.com
US IR Tel: +1 (443) 213-0505
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its
proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional
level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's
proprietary RNA chemistries and
delivery systems are designed to improve the stability of our
molecules and enhance effective delivery
to target cells, providing a powerful modular technology well
suited to tackle life-threatening diseases.
For more information, please visit:
https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEAAAPFFNPFAF
(END) Dow Jones Newswires
December 19, 2018 02:00 ET (07:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024